U.S. Government exercised 1st option for additional 100 million doses of Moderna’s COVID-19 vaccine
On Dec. 11, 2020, Moderna announced that the U.S. government has exercised its option to purchase an additional…
-
-
Roche partnered with Moderna to include SARS-CoV-2 antibody test in ongoing COVID-19 vaccine trials
On Dec. 10, 2020, Roche announced a partnership with Moderna to utilise the Elecsys Anti-SARS-CoV-2 S antibody test…
-
ImmunityBio’s hAd5 T-Cell COVID-19 vaccine candidate showed complete protection of airways
On Dec. 10, 2020, ImmunityBio announced its COVID-19 vaccine candidate protected nasal and lung airways of non-human primates…
-
Moderna announced first participants dosed in phase 2/3 study of COVID-19 vaccine candidate in adolescents
On Dec. 10, 2020, Moderna announced that the first adolescent participants had been dosed in the Phase 2/3…
-
Roche partnered with Moderna to include SARS-CoV-2 antibody test in ongoing COVID-19 vaccine trials
On Dec. 9, 2020, Roche announced a partnership with Moderna to utilise the Elecsys Anti-SARS-CoV-2 S antibody test…
-
Switzerland exercised increased option for 7.5 million doses of mRNA vaccine against COVID-19 (mRNA-1273)
On Dec. 8, 2020, Moderna announced the Swiss Federal Government had increased its confirmed order commitment from 4.5…
-
Mount Sinai researchers advanced universal influenza virus vaccine
On Dec. 7, 2020, an universal influenza virus vaccine, which produces antibodies that target the part of the…
-
Canada exercised increased option for total of 40 million doses of mRNA vaccine candidate against COVID-19
On Dec. 7, 2020, Moderna announced that the Canadian Government had increased its confirmed order commitment by 20…
-
Chimerix announced FDA acceptance of NDA for brincidofovir as a medical countermeasure for smallpox
On Dec. 7, 2020, Chimerix announced the U.S. Food and Drug Administration (FDA) had accepted the filing of a…
-
Matinas BioPharma announced collaboration with NIAID to evaluate Gilead’s antiviral remdesivir
On Dec. 7, 2020, Matinas BioPharma announced that they planned to collaborate with the National Institute of Allergy…
-
INOVIO dosed first subject in phase 2 segment of INNOVATE phase 2/3 trial for INO-4800 to prevent COVID-19
On Dec. 7, 2020, Inovio Pharmaceuticals announced it had dosed its first subject in a Phase 2 clinical…
-
Biotechnology | Chemistry | Disease | Oncology | Radiology
Dr. James Lim and Lakshana Sreenivasan discovered that certain immune signals may help medulloblastoma resist chemotherapy
On Dec. 5, 2020, Dr. James Lim and Lakshana Sreenivasan discovered that certain immune signals may help medulloblastoma…
-
FDA authorized first COVID-19 and flu combination test for use with home-collected samples
On Dec. 4, 2020, the U.S. Food and Drug Administration (FDA) authorized the first diagnostic test for at home collection…
-
High-dose influenza vaccine showed no additional benefit for heart disease patients
On Dec. 4, 2020, it was reported in JAMA that high-dose influenza (commonly known as flu) vaccines are…
-
Peanut allergy treatment significantly lowered risk of life-threatening reactions in preschoolers
On Dec. 3, 2020, a new study by researchers at the University of British Columbia and BC Children’s…
-
Moderna updated on clinical development and production of Its COVID-19 vaccine candidate
On Dec. 3, 2020, Moderna announced in a letter to the editor published in the New England Journal…
-
AXIM Biotechnologies filed patent for virus binding recombinant protein for SARS-CoV-2 and began manufacturing
On Dec. 3, 2020, AXIM Biotechnologies announced the development and patent filing for an enzyme-linked immunosorbent assay (ELISA)-based…
-
INOVIO expanded global manufacturing consortium for COVID-19 vaccine candidate with Kaneka Eurogentec
On Dec. 3, 2020, Inovio Pharmaceuticals announced the execution of an agreement with Kaneka Eurogentec an affiliate of…
-
BD to invest $12 billion in pre-fillable syringe manufacturing capacity over next four years
On Dec. 2, 2020, BD (Becton, Dickinson) announced plans to invest approximately $1.2 billion over a 4-year period…
-
Biotechnology | Diagnostics | Disease | Infectious Disease | Medicine | Non-Profit Research | Therapeutics
University of Oregon opened the Phil and Penny Knight Campus for Accelerating Scientific Impact
On Dec. 2, 2020, the University of Oregon opened the Phil and Penny Knight Campus for Accelerating Scientific…
-
Oxford Immunotec signed distributor agreement with RIKEN Genesis for T-SPOT Discovery SARS-CoV-2 Kit in Japan
On Dec. 2, 2020, Oxford Immunotec announces an exclusive distribution agreement with RIKEN Genesis in Japan. Under the…
-
Biotechnology | COVID-19 | Therapeutics | WHO
Mateon announced development update for ARTIVEDA/ARTISHIELD against COVID-19
On Nov. 30, 2020, Mateon Therapeutics announced that the India arm of ARTI-19 global study was on track…
-
City of Hope coronavirus vaccine produced strong immunity in preclinical research
On Nov. 30, 2020, a City of Hope investigational vaccine produced strong protective immunity against SARS-CoV-2, including neutralizing antibodies…
-
Moderna announced primary efficacy analysis in phase 3 COVE study for COVID-19 vaccine candidate
On Nov. 30, 2020, Moderna announced that the primary efficacy analysis of the Phase 3 study of mRNA-1273…
-
Innovation Pharma’s COVID-19 clinical trial supported development of Brilacidin as ‘Pan-Coronavirus’ therapeutic
On Nov. 30, 2020, Innovation Pharmaceuticals announced additional independent preliminary laboratory research suggests Brilacidin, the Company’s flagship defensin…
-
Novavax announced COVID-19 vaccine clinical development progress
On Nov. 30, 2020, Novavax announced that two of the three planned late-stage efficacy trials for NVX-CoV2373 sponsored…
-
Lonza expanded development and manufacturing aapabilities at Bend facility
On Nov. 30, 2020, Lonza announced $10 million investment in its Bend, Oregon facility. Originally known as Bend…
-
Moderna amended supply agreement with UK Government for 2 million doses of mRNA COVID-19 vaccine
On Nov. 29, 2020, Moderna announced a supply agreement with the United Kingdom (UK) government for an additional…
-
RedHill Biopharma expanded U.S.-based manufacturing capacity of opaganib for COVID-19
On Nov. 25, 2020, RedHill Biopharma announced partnerships with two leading, U.S.-based manufacturers for large-scale manufacturing of opaganib….
-
Moderna announced EC approval of purchase agreement for 80 million doses of mRNA COVID-19 vaccine
On Nov. 25, 2020, Moderna announced that the European Commission (EC) has approved an agreement to secure 80…
